Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAKD0I)

• Drug Name: AVX-470 Drug Info
• Synonyms: Anti-TNF antibody (oral, IBD), Avaxia Biologics

Indication

Disease Entry	ICD 11	Status	REF
Inflammatory bowel disease	DD72	Phase 1	[1]
Ulcerative colitis	DD71	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DMAKD0I

Molecule-Related Drug Atlas

Drug(s) Targeting Tumor necrosis factor (TNF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[4]
Nafamostat	DMU1XOD	Pancreatitis	DC31-DC34	Approved	[5]
Pentoxifylline	DMU3DNC	Alcoholic hepatitis	DB94.1	Approved	[6]
Lenalidomide	DM6Q7U4	Adult T-cell leukemia/lymphoma		Approved	[7]
Enbrel	DM7RNP3	Arthritis	FA20	Approved	[8]
Golimumab	DMHZV7X	Psoriatic arthritis	FA21	Approved	[9]
Certolizumab	DM5CL9Z	Rheumatoid arthritis	FA20	Approved	[10]
Etanercept	DMCV109	Arthritis	FA20	Approved	[11]
Adalimumab	DMQMV1B	Crohn disease	DD70	Approved	[12]
Infliximab	DMH7OIA	Crohn disease	DD70	Approved	[13]

Drug(s) Targeting Tumor necrosis factor receptor type I (TNF-R1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VB-111	DMX04CA	Malignant glioma	2A00.0	Phase 3	[14]
Drug 2862277	DM8WU3O	Acute lung injury	NB32.3	Phase 2	[15]
GSK1995057	DMC14KV	Adult respiratory distress syndrome	CB00	Phase 1	[16]
Anti-IFN gamma	DMXI185	Alopecia	ED70	Terminated	[3]
TNFR1 NAM	DMPTQEG	Multiple sclerosis	8A40	Investigative	[15]
NM-9405	DMKMBSJ	Rheumatoid arthritis	FA20	Investigative	[15]
TNFmab	DM4T0ZF	Rheumatoid arthritis	FA20	Investigative	[3]
ADS-0101	DMP7IS0	Chronic obstructive pulmonary disease	CA22	Investigative	[15]
Recombinant human TNF receptor	DMLYQWV	Arthritis	FA20	Investigative	[3]
TNFcept	DMAGI7K	Rheumatoid arthritis	FA20	Investigative	[3]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tumor necrosis factor (TNF)	TTF8CQI	TNFA_HUMAN	Inhibitor	[2]
Tumor necrosis factor receptor type I (TNF-R1)	TTG043C	TNR1A_HUMAN	Not Available	[3]

References

• [1] ClinicalTrials.gov (NCT01759056) Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65.
• [4] Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
• [5] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [6] Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20.
• [7] Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
• [8] Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61.
• [9] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [10] Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
• [11] The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
• [12] Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7.
• [13] Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9.
• [14] Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.Clin Cancer Res.2013 Jul 15;19(14):3996-4007.
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1870).
• [16] Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-alpha receptor 1. J Clin Immunol. 2013 Oct;33(7):1192-203.